Neurosurgical Delivery of Therapies for Inherited Metabolic and Genetic Brain Disorders

Status: draft · Last updated 2026-11-18 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • AADC deficiency: bilateral intraputaminal AAV2 gene therapy gave durable motor gains (more than 5 years), better in younger children, with transient dyskinesia . MR-guided cannula delivery confirms coverage, with no adverse events attributed to the cannula .
  • CLN2 (Batten): intraventricular cerliponase alfa every 2 weeks slows decline (0.27 vs 2.12 points per 48 weeks) . Devices fail and get infected: complications in 12 of 26 operations, and revised reservoirs last much shorter (301 vs 2,317 days) .
  • SMA with fusion: laminectomy window (9 of 11 successful) or intrathecal port (2 of 8 leaks, no infections) .
  • Pipeline: intrathecal ASOs (zorevunersen for Dravet ); ICV and intrathecal gene therapy for Rett . Expect more access-device work.

Landmark papers

  • Schulz et al., N Engl J Med 2018: intraventricular cerliponase alfa for CLN2. Decline was 0.27 vs 2.12 points per 48 weeks, at the cost of device failures and infections .
  • Tai et al., Mol Ther 2022: intraputaminal eladocagene exuparvovec in 26 children with AADC deficiency, with motor and cognitive gains sustained beyond 5 years .
  • Laux et al., N Engl J Med 2026: zorevunersen for Dravet syndrome, an investigational, potentially disease-modifying ASO for a developmental and epileptic encephalopathy, given intrathecally .

A new role for pediatric neurosurgeons is getting a drug or vector past the blood–brain barrier. Enzyme replacement, gene therapy and antisense oligonucleotides (ASOs) for rare inherited disorders increasingly need:

The neurosurgeon owns the targeting, the device and its complications, and should be part of the treating team from the start (see caveats).

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:genetic_therapy_delivery:2cf398ed8349b088© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Coronal brain with bilateral frontal cannulas and infusate filling each putamen; an axial midbrain with infusion clouds in the substantia nigra and ventral tegmental area; a frontal reservoir with a ventricular catheter and a chest-port variant; and lumbar intrathecal access through a laminectomy window between rods and screws, or by a subcutaneous port(A) INTRAPUTAMINAL INFUSION (CORONAL)infusate cloud filling the putamencannula from a frontal burr holeMRI-guided intraputaminal AAV2 infusion, both sides(B) MIDBRAIN TARGET (AXIAL)substantia nigraventral tegmental areared nucleusconvection-enhanced delivery; cannula tipsenter from above (projected as dots)(C) INTRAVENTRICULAR ACCESSreservoir dome under the scalp;needle for repeated infusionsfrontal catheter into thelateral ventriclevariant: cathetertunneled to achest-sited port(D) INTRATHECAL, AFTER FUSIONlaminectomy window, needleinto the thecal sacrods and screwsvariant: subcutaneous portwith an intrathecal catheterthecalsacport
Neurosurgical delivery routes for genetic therapies. (a) Bilateral stereotactic intraputaminal infusion of an AAV2 vector (eladocagene exuparvovec) under MRI guidance, with the infusate (shown as a tinted cloud) filling the putamen. (b) Alternative midbrain target: convection-enhanced delivery to the substantia nigra and ventral tegmental area. (c) Intraventricular access device (reservoir with frontal ventricular catheter) for repeated cerliponase alfa infusions, with a chest-sited port variant. (d) Intrathecal access after spinal fusion: a lumbar laminectomy window, or a subcutaneous port with an intrathecal catheter. Not to scale.

AADC deficiency: intraputaminal gene therapy

CLN2 disease: intraventricular enzyme replacement

Spinal muscular atrophy: intrathecal access after spinal fusion

In the pipeline

Related topics

References

  1. Pearson TS, Gupta N, San Sebastian W, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons. Nat Commun 2021;12(1):4251. doi:10.1038/s41467-021-24524-8. PMID 34253733. verified
  2. Tai CH, Lee NC, Chien YH, et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol Ther 2022;30(2):509–518. doi:10.1016/j.ymthe.2021.11.005. PMID 34763085. verified
  3. Curry DJ, Pearl PL, Stone SSD, et al. Pharmacodynamics, efficacy, and safety of intraputaminal eladocagene exuparvovec administered to pediatric patients with aromatic L-amino acid decarboxylase deficiency using an MR-compatible cannula: 48 weeks of follow-up. J Inherit Metab Dis 2026;49(2):e70151. doi:10.1002/jimd.70151. PMID 41724580. verified
  4. Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med 2018;378(20):1898–1907. doi:10.1056/NEJMoa1712649. PMID 29688815. verified
  5. Craven CL, Gissen P, Bower R, et al. A survival analysis of ventricular access devices for delivery of cerliponase alfa. J Neurosurg Pediatr 2022;29(1):115–121. doi:10.3171/2021.7.PEDS21129. PMID 34624852. verified
  6. Potaczek T, Duda S, Adamczyk J. Surgical access for intrathecal therapy in spinal muscular atrophy with spinal fusion: long-term outcomes of lumbar laminectomy. J Clin Med 2025;14(12):4280. doi:10.3390/jcm14124280. PMID 40566025. verified
  7. Flotats-Bastardas M, Hahn A, Schwartz O, et al. Multicenter experience with nusinersen application via an intrathecal port and catheter system in spinal muscular atrophy. Neuropediatrics 2020;51(6):401–406. doi:10.1055/s-0040-1715481. PMID 33091940. verified
  8. Laux L, Sullivan J, Perry MS, et al. Zorevunersen in children and adolescents with Dravet syndrome. N Engl J Med 2026;394(10):969–982. doi:10.1056/NEJMoa2506295. PMID 41780062. verified
  9. Samanta D. Disease-modifying therapies for Rett syndrome: a review for neurologists. Front Neurol 2026;17:1766679. doi:10.3389/fneur.2026.1766679. PMID 41641323. verified

Verification (2026-11-18):

Caveats: